(Q53372791)

English

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

semaglutide

5 May 2024

1

object named as

Bo Ahrén

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

author name string

Luis Masmiquel

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

Harish Kumar

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

Mehmet Sargin

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

Julie Derving Karsbøl

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

Sanja Hald Jacobsen

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

Francis Chow

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

publication date

3 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

341-354

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight management in type 2 diabetes: current and emerging approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 and appetite

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient perspectives on once-weekly medications for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of weight management in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930092-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(17)30092-X

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28385659

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53372791&oldid=2145723238"